Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Deferred Revenue (2016 - 2025)

Editas Medicine (EDIT) has disclosed Current Deferred Revenue for 11 consecutive years, with $56.2 million as the latest value for Q1 2025.

  • On a quarterly basis, Current Deferred Revenue fell 18.41% to $56.2 million in Q1 2025 year-over-year; TTM through Mar 2025 was $56.2 million, a 18.41% decrease, with the full-year FY2024 number at $60.4 million, up 635.01% from a year prior.
  • Current Deferred Revenue was $56.2 million for Q1 2025 at Editas Medicine, down from $60.4 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $89.4 million in Q1 2021 to a low of $8.2 million in Q1 2023.
  • A 5-year average of $54.1 million and a median of $68.9 million in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 88.07% in 2023, then soared 737.95% in 2024.
  • Editas Medicine's Current Deferred Revenue stood at $72.2 million in 2021, then decreased by 4.62% to $68.9 million in 2022, then tumbled by 88.07% to $8.2 million in 2023, then skyrocketed by 635.01% to $60.4 million in 2024, then fell by 6.99% to $56.2 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Current Deferred Revenue are $56.2 million (Q1 2025), $60.4 million (Q4 2024), and $68.9 million (Q3 2024).